Vinlon 1mg Injection (Vincristine)

Vinlon 1mg Injection is an anticancer medicine with active ingredient Vincristine. This injection is prescribed to treat a wide range of cancers, including breast cancer, non-small cell lung cancer, pancreatic cancer, kidney cancer, blood cancer, multiple myeloma, lymphomas and bone cancer.

It works by blocking the replication of genetic material in cancer cells to control the spread of cancer. This injection is given intravenously by a doctor or experienced nurse. It is not self-administerable.

Chemotherapy, Breast Cancer

The human body reacts differently to Vinlon 1mg Injection(Vincristine 1mg). Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention. Some of the common side effects of Vinlon 1mg:
● Nausea and vomiting
● Constipation
● Loss of appetite
● Hair loss
● Fatigue
● Muscle weakness
● Numbness or tingling in the hands and feet (peripheral neuropathy)
● Increased risk of infection
● Easy bruising or bleeding
● Mouth sores
● Changes in mood or behavior
● Difficulty sleeping
However, if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.

Vinlon 1mg Injection(Vincristine 1mg) is a powerful anticancer medicine that can only be given intravenously by a doctor or nurse under strict medical supervision. It is not self-administerable. Dosage and duration of the treatment are determined by the doctor as per the patient's health condition and type & stage of the cancer. ● Sandier, S. G., Tobin, W., & Henderson, E. S. (1969). Vincristine‐induced neuropathy: A clinical study of fifty leukemic patients. Neurology, 19(4), 367-367.
● Bradley, W. G., Lassman, L. P., Pearce, G. W., & Walton, J. N. (1970). The neuromyopathy of vincristine in man: clinical, electrophysiological and pathological studies. Journal of the neurological sciences, 10(2), 107-131.
● CARBONE, P. P., Bono, V., FREI III, E. M. I. L., & BRINDLEY, C. O. (1963). Clinical studies with vincristine. Blood, 21(5), 640-647.
● ROSENTHAL, S., & KAUFMAN, S. (1974). Vincristine neurotoxicity. Annals of Internal Medicine, 80(6), 733-737.
● Škubník, J., Pavlíčková, V. S., Ruml, T., & Rimpelova, S. (2021). Vincristine in combination therapy of cancer: emerging trends in clinics. Biology, 10(9), 849.

Instructions if you miss a dose

● Sandier, S. G., Tobin, W., & Henderson, E. S. (1969). Vincristine‐induced neuropathy: A clinical study of fifty leukemic patients. Neurology, 19(4), 367-367.
● Bradley, W. G., Lassman, L. P., Pearce, G. W., & Walton, J. N. (1970). The neuromyopathy of vincristine in man: clinical, electrophysiological and pathological studies. Journal of the neurological sciences, 10(2), 107-131.
● CARBONE, P. P., Bono, V., FREI III, E. M. I. L., & BRINDLEY, C. O. (1963). Clinical studies with vincristine. Blood, 21(5), 640-647.
● ROSENTHAL, S., & KAUFMAN, S. (1974). Vincristine neurotoxicity. Annals of Internal Medicine, 80(6), 733-737.
● Škubník, J., Pavlíčková, V. S., Ruml, T., & Rimpelova, S. (2021). Vincristine in combination therapy of cancer: emerging trends in clinics. Biology, 10(9), 849.